LONDON, Oct 11 (Reuters) - AstraZeneca has signed adeal to co-promote Johnson & Johnson's novel prostatecancer medicine in Japan, giving the British company a new drugrevenue stream and bolstering its Japanese presence.
Financial terms of the agreement, announced by AstraZenecaon Friday, were not disclosed.
The drug, abiraterone, was submitted for regulatory approvalin Japan in July 2013. It is already on the market in the UnitedStates and Europe, where it is sold under the brand name Zytiga.
"This deal is a strong strategic fit for AstraZeneca,reinforcing both our focus on oncology as a core therapy areaand Japan as one of our key growth drivers," said Marc Dunoyer,executive vice president for global products and portfoliostrategy at AstraZeneca.
- Health Care Industry